Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352898
Status:
COMPLETED
Last Update Posted:
2016-10-07
First Post:
2006-07-14
Brief Title:
Immunogenicity Safety of Measles-mumps-rubella-varicella Vaccine MeMuRu-OKA Compared to Priorix Given With Varilrix
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Comparative Study Evaluating the Immunogenicity Safety of MeMuRu-OKA Vaccine Measles-mumps-rubella Vaccine Priorix Co-administered With Varicella Vaccine Varilrix in Children Primed With Both Measles-mumps-rubella Varicella Vaccines
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Since measles-mumps-rubella MMR and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life a combined measles-mumps-rubella-varicella MeMuRu-OKA vaccine is fully justified Such a combined vaccine was developed and extensively studied in susceptible children In countries where varicella mass-vaccination is already implemented a transition period is necessary as children who started with separate first-dose vaccinations of MMR and varicella will receive a single shot of the combined vaccine as the second dose To account for those situations this study will evaluate the effect of the combined measles-mumps-rubella-varicella vaccine given in place of separate MMR and varicella vaccines as a second dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None